Psoriasis. Definition and causes Types GP management Pitfalls Hospital treatments.

Slides:



Advertisements
Similar presentations
Epidemiology, presentation, complication and management.
Advertisements

IDENTIFICATION AND MANAGEMENT
Ramesh Mehay Programme Director (Bradford VTS)
Psoriasis. Definition Chronic plaque psoriasis (psoriasis vulgaris) is a chronic inflammatory skin disease characterised by well demarcated erythematous.
Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open label study Jacobi A et al. One of authors Braeutigam M belongs to clinical.
Psoriasis By Sandra E. Valenzuela 5/5/02 Definition A Chronic (long lasting) skin disease characterized by scaling and inflammation. Scaling occurs when.
Psoriasis Definition: is a chronic, sometimes acute, non- contagious common condition of the skin Definition: is a chronic, sometimes acute, non- contagious.
Pharmacology-4 PHL 425 Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
Psoriasis: Treatment and Management Ann Davies Clinical Nurse Specialist in Dermatology University Hospital Of Wales, Cardiff.
Psoriasis & Skin Cancer
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, PsoriasisPsoriasis.
Psoriasis. Definition and causes Definition and causes Types Types GP management GP management Pitfalls Pitfalls Hospital treatments Hospital treatments.
PSORIASIS. Psoriasis is a disease which affects the skin and joints. Psoriasis is a disease which affects the skin and joints.skinjointsskinjoints It.
BADBIR BAD Biologic Interventions Register Dr Kathy McElhone 27 th June 2012.
Psoriasis and Skin Cancer Edward Pritchard. Long Cases You could get these! Last year’s finals! - Patient with recurrent SCC, with no symptoms. History.
Psoriasis By Anna Hodge Objectives Recognise psoriasis Know the first line treatments for psoriasis Use topical corticosteroids safely Know.
Psoriasis By: Angie Vasquez and Marsa Eglip. Introduction Basic description of psoriasis Basic description of psoriasis Symptoms Symptoms Genetic cause.
SHRI GANASAYA NAMAHA. AN UPDATE ON PSORIASIS BY DR. MAHESH MATHUR, MD,DVD,DCP (UK) MD,DVD,DCP (UK)
Psoriasis. Definition and causes Types GP management Pitfalls Hospital treatments Case studies.
Psoriasis. Definition l Psoriasis is a recurrent,chronic,inflammatory disease of the skin characterized by red papules or plaques covered by silvery white.
Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
BAD Biologic Interventions Register (BADBIR ) An update November 2010.
A Red Scaly Rash Small Group Teaching Problem Based Learning Dermatology Department College of Medicine King Saud University.
British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.
1 PsoriasisPsoriasis Dr. Majdy Naim. 2 PrevalencePrevalence Psoriasis occurs in 2% of the world’s population Psoriasis occurs in 2% of the world’s population.
Alexandra Pyle Bsc (Hons) Registered Nurse. What is Psoriasis?  Psoriasis is a chronic inflammatory skin disorder characterised by thickened, scaly plaques.
Pathologies of the Integumentary System
 exact cause unknown  defect of the skin that impairs its function as a barrier, combined with an abnormal function of the immune system, are believed.
PSORIASIS Ben Basger Basgers Pharmacy North Bondi Pharmacy Practice, The University of Sydney.
Psoriasis and Other Papulosquamous Disease. Definitions – Psoriasis is the most common chronic papulosquamous disease – The classic lesion of psoriasis.
BAD Biologic Interventions Register (BADBIR ) An update November 2009.
Pharmacology-4 PHL 425 Fourth Lecture By Abdelkader Ashour, Ph.D. Phone:
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Eczema & Psoriasis Dr. Jerald E. Hurdle Kennebec Medical Consultants Waterville, ME
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Disease modified Anti-rheumatic drugs ( DMARD)
TRIGGER  Ali is a 50-year-old engineer who presented to Dr. Khalid with itching all over his body for the last few weeks. Recently he has noticed that.
PSORIASIS BY: Jennifer Teen Health 8 Old Orchard Junior High School.
Psoriasis Victoria Lund. Overview Causes skin cells to mature in less than a week (normally it takes days) The immune system send signals to increase.
Psoriasis disease psoriasis  Content  Definition  Name of the causing bacteria  Common types of psoriasis  Diagnosis  causes.
Chapter 5 Psoriasis.
Psoriasis and Other Papulosquamous Disease
Diagnosis and Management of Psoriasis and Psoriatic Arthritis
How can pharmacists help improve outcomes for patients with psoriasis?
Psoriasis.
By AFSAR FATHIMA Dept. of Pharmacology
Presentation topic Psoriasis Disease
Diagnosis and treatment algorithm for psoriasis
Psoriasis John Sugrue.
Department of Dermatology
Psoriasis داء الصدفية.
Retinoids used in dermatology
Psoriasis Tutoring By Alaina darby.
A Red Scaly Rash ..
treatment of psoriasis (Evidence -based Dermatology) H.Mozayyeni
Psoriasis and Skin Cancer
WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in
Skin Conditions II. Skin Conditions II Corn and Calluses.
Dermatology update in common cases and treatment
Clive Tubb CNS Dermatology
Kate Blake Lead Nurse Dermatology
Presentation transcript:

Psoriasis

Definition and causes Types GP management Pitfalls Hospital treatments

Psoriasis Definition A chronic, non-infectious, inflammatory skin disorder, with well defined, erythematous plaques & large adherent silvery scales Prevalence 1.5-3% Age onset 20-30y or 50-60y

Psoriasis Epidermal hyperproliferation Vascular dilatation Inflammatory infiltrate

What causes psoriasis ? T cell mediated autoimmune disease → increased keratinocyte proliferation Environmental and genetic factors

Psoriasis GeneticsGenetics 40% have FHx40% have FHx 73% monozygotic twins concordant v 20% dizygotic twins73% monozygotic twins concordant v 20% dizygotic twins 1 st degree relatives have 4-6 fold increased risk1 st degree relatives have 4-6 fold increased risk Environmental triggersEnvironmental triggers

GP Management Time (for proper examination and to communicate with the patient) Explanation Information and support sources (patient.co.uk, psoriasis- association.org.uk) Follow-up

GP Management Emollients Bath oils Site-specific topical treatments

Topical treatments Vitamin D analogues Dovonex (calcipotriol) Dovobet (calcipotriol & betamethasone) Silkis (calcitriol) Curatorderm (tacalcitol) Zorac (tazarotene) Dovonex cream and scalp application no longer available

Topical treatments Tar (Carbo-dome) (Exorex) Psoriderm (Alphosyl HC) Sebco (Cocois) Tar-based bath oils & shampoos

Topical Treatments Steroids Often in conjunction with Vit D analogue as Dovobet or separate steroid Eumovate (Trimovate) Scalp preparations (eumovate to dermovate strength) BE CAREFUL (but not mean)

Topical Treatments Dithranol Dithrocream Micanol Psorin Stains skin Has to be washed off Start and low strength and build up

Topical treatments Nails difficult potent topical steroids dovonex tazarotene systemic therapy

Topical Treatments Scalp Remove scale first Cocois or Sebco messy but effective Tar or salicylic acid shampoo Topical steroids if necessary for short periods

Types of psoriasis Plaque Guttate Rupioid Unstable Pustular Erythrodermic ?palmo-plantar pustulosis

Guttate psoriasis

Pustular psoriasis

Erythrodermic psoriasis

Plantar pustulosis

Acrodermatitis continua of Hallopeau

Pitfalls 'It's not working Doc' It did work, but then he stopped using it and the psoriasis returned It was too greasy/time- consuming/smelly so he stopped using it He wasn't applying it properly It really didn't work

Hospital Treatment Out-patient advice and support UVB PUVA Acitretin Methotrexate Ciclosporin Biologics Admission (tar, other topicals)

UVB phototherapy Suitability – age, PH skin cancer, medication, radiotherapy, photosensitive disease X3 / week for ~6 weeks Shield genitalia, uninvolved sites SE burning (30%) ↑ risk skin cancer (screen yearly if >150 treatments)

PUVA Suitability – as for UVB + CI in renal/hepatic disease, cataracts, pregnancy, children X2 / week for ~6-8 weeks Need eye protection for 24 h after psoralen SE burning, nausea, itch ↑ risk skin cancer (screen yearly if >150 treatments)

Systemic therapy acitretin methotrexate ciclosporin

7-20% of patients with psoriasis have arthritis

Acitretin mec: affects keratinocyte differentiation CI: ? fertile women (as must avoid pregnancy for 2 years) SE: dry lips, teratogenicity, abnormal LFT, lipids, DISH

Methotrexate mec: inhibits DNA synthesis by inhibiting dihydrofolate reductase → reduces proliferation of lymphocytes + keratinocytes CI: pregnancy, lactation, infection, liver/renal disease, peptic ulcers given once weekly SE: anorexia, nausea, myelosuppression, hepatotoxicity, mouth ulcers, pulmonary toxicity, oligospermia, skin cancer Interactions: NSAIDs, septrin, trimethoprim, penicillin, phenytoin

Ciclosporin Mec Inhibits T cell activation CI uncontrolled HBP, malignancy, infection SE HBP, nephrotoxicity, skin cancer, other malignancy, gum hypertrophy Not recommended for long term treatment

New Biologicals Anti TNF drugs Infliximab, etanercept, adalimumab Targeted T - cell therapy alefacept (binds CD2 & blocks LFA3) efalizumab (binds to LFA-1 & blocks ICAM-1) Anti-IL 17 receptor antibodies Brodalumab Ixekizumab

GP Issues Know what your patient is on (?record as outside script on EMIS) Know what monitoring you are responsible for Keep a look out for myelosuppression Don't be afraid of your local Derm department!

SIGN 121 Patients with psoriasis or psoriatic arthritis should have an annual review with their GP involving the following: ƒdocumentation of severity using DLQI ƒscreening for depression ƒassessment of vascular risk (in patients with severe disease) ƒassessment of articular symptoms ƒoptimisation of topical therapy ƒconsideration for referral to secondary care

Streptococcal theory Streptococcal infection can:  super-antigen immune stimulation  very high cytokine excretion, especially TNF-α

In guttate psoriasis, all strep isolates from the throat stimulate this pathway. Once activated, these T cells infiltrate the skin, however the thereafter pathogenic pathways diverge: keratinocyte death & exfoliation in scarlet fever keratinocyte proliferation in guttate psoriasis

Case Studies Paul, age 45 Carpet fitter Large plaque psoriasis knees, elbows, natal cleft. Hand and nail involvement

Case studies Robert, age 35 Psoriasis since teens Lives in a hostel, alcoholic

Case studies Anne, age 15 Recent onset guttate psoriasis Wants skin to be clear for sister’s wedding

Case studies David, age 25 Severe psoriasis Has had multiple admissions, MTX, Ciclosporin, acitretin, UVB Treatment so far has produced partial success only Very keen to improve his skin as finds holding down a job very difficult